Immatics N.V. (IMTX)
| Market Cap | 1.05B |
| Revenue (ttm) | 60.00M |
| Net Income (ttm) | -107.77M |
| Shares Out | 102.99M |
| EPS (ttm) | -1.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,970 |
| Open | 10.42 |
| Previous Close | 10.42 |
| Day's Range | 10.13 - 10.64 |
| 52-Week Range | 6.46 - 13.16 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | May 14, 2024 |
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203... [Read more]
News
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Houston, Texas and Tuebingen, Germany, March 21, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
Immatics Announces Pricing of $175 Million Public Offering
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...
Immatics Announces Proposed Public Offering
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...
Immatics Announces Third Quarter 2023 Financial Results and Business Update
Tuebingen, Germany and Houston, TX, November 14, 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types Regulatory activities und...
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Appointment effective as of September 14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX),...
Immatics shares rise on Moderna cancer collaboration
Immatics NV shares IMTX, -2.87% gained more than 6% premarket on Monday after the company announced a collaboration with Moderna Inc. MRNA, -0.66% to research and develop new cancer therapies. The par...
Moderna, Immatics to work jointly on cancer vaccines
Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone paym...
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Cambridge, Massachusetts and Tuebingen , Germany , September 11 , 2023 – Moderna, Inc. (NASDAQ: MRNA, “Moderna”) and Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical compan...
Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's ...
Immatics Announces Second Quarter 2023 Financial Results and Business Update
Tuebingen, Germany and Houston , TX, August 17 , 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
Tuebingen, Germany and Houston, Texas , August 10 , 202 3 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redir...
Immatics shares jump after investment from Bristol Myers Squibb
Shares of Immatics N.V. IMTX, +0.08% gained more than 8% premarket on Monday after the clinical-stage biopharma company said it had received a $35 million equity investment from Bristol Myers Squibb C...
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
Tuebingen , Germany and Houston , TX , Ju ly 24 , 202 3 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...
Immatics Announces First Quarter 2023 Financial Results and Business Update
Tuebingen , Germany and Houston, TX , May 16 , 20 2 3 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
Tuebingen, Germany & Houston, May 1, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer im...
Immatics Announces Full Year 2022 Financial Results and Corporate Update
Tuebingen , Germany and Houston, TX , March 2 1 , 20 2 3 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redire...
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Tuebingen , Germany and Houston, Texas , November 1 7 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-re...
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
H ouston, Texas and Tuebingen , Germany , October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redi...
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
Company to host conf e rence call today, October 10 , at 8:30 am E D T / 2:30 pm CEST
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME. In preclinical studies, IMA402 demonstrated enhanced anti-tumor acti...
Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME
H ouston, Texas and Tuebingen , Germany , August 23 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redi...
Immatics Announces Second Quarter 2022 Financial Results and Business Update
Tuebingen , Germany and Houston, Texas , August 9 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redire...